Sep 11, 2023 / 02:40PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Well, thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. We're very pleased to have Biogen. Joining us today from the company is Chris Viehbacher, CEO. Chris, thanks so much for being here.
Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Well, thanks so much, Chris. I really appreciate the time today. I know it's a busy time at Biogen.
Questions and Answers:
Terence C. Flynn - Morgan Stanley, Research Division - Equity AnalystMaybe to start, I thought we could talk about what's some of your key priorities are over the next year?
Christopher A. Viehbacher - Biogen Inc. - President, CEO & Director
Yes. Thanks, Terence. It has been a busy, I think it's 8 months, maybe 9 months now. I